Bone Therapeutics (Group)

https://www.bonetherapeutics.com

Bone Therapeutics is a leading biotech company focused on the development of innovative products to address high unmet needs in orthopedics and bone diseases. The Company has a broad, diversified portfolio of bone cell therapies and an innovative biological product in later-stage clinical development, which target markets with large unmet medical needs and limited innovation. Bone Therapeutics is developing an off-the-shelf protein solution, JTA-004, which is entering Phase III development for the treatment of pain in knee osteoarthritis. Positive Phase IIb efficacy results in patients with knee osteoarthritis showed a statistically significant improvement in pain relief compared to a leading viscosupplement. The clinical trial application (CTA) for the pivotal Phase III program has been approved by the relevant authorities allowing the start of the study. Bone Therapeutics’ other core technology is based on its cutting-edge allogeneic cell therapy platform (ALLOB) which can be stored at the point of use in the hospital, and uses a unique, proprietary approach to bone regeneration, which turns undifferentiated stem cells from healthy donors into bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery, and are produced via a proprietary, scalable cutting-edge manufacturing process. Following the CTA approval by the Belgian regulatory authority, the Company is ready to start the Phase IIb clinical trial with ALLOB in patients with difficult tibial fractures, using its optimized production process. The ALLOB platform technology has multiple applications and will continue to be evaluated in other indications including spinal fusion, osteotomy and maxillofacial and dental applications. Bone Therapeutics’ cell therapy products are manufactured to the highest GMP (Good Manufacturing Practices) standards and are protected by a broad IP (Intellectual Property) portfolio covering ten patent families as well as knowhow. The Company is based in the BioPark in Gosselies, Belgium. Further information is available at www.bonetherapeutics.com. *

	Start	2006-01-01 established

	Street	7 Rue Auguste Piccard
	City	6041 Gosselies
	Tel	+32-2-529-5990
		Address record changed: 2024-01-05

Basic data	Employees	C: 51 to 100 (2018-12-31)
	Currency	EUR
	Annual sales	5,079,000 (income, operating, total, consolidated (2018) 2018-12-31)
	Profit	-14,011,000 (2018-12-31)
	Cash	8,174,000 (2018-12-31)

		* Document for »About Section«: Bone Therapeutics S.A.. (4/29/20). "Press Release: Bone Therapeutics Secures EUR 11.0 Million Financing". Gosselies.

		Record changed: 2024-02-12